Liz Thompson

Medicine & Life Sciences

1. Pancreatic Neoplasms 100%
2. Adenocarcinoma 59%
3. Neoplasms 52%
4. Neoadjuvant Therapy 36%
5. Tumor Microenvironment 32%
6. T-Lymphocytes 26%
7. Survival 21%
8. Organoids 17%
9. Neoplasm Metastasis 16%
10. Drug Therapy 16%
11. Pancreatic Cyst 15%
12. Recurrence 14%
13. Pathology 14%
14. Pancreas 13%
15. GVAX vaccine 13%
16. Neuroendocrine Tumors 12%
17. Colorectal Neoplasms 12%
18. Mutation 12%
19. Tumor-Infiltrating Lymphocytes 11%
20. Immunotherapy 11%
21. Ligands 10%
22. Therapeutics 10%
23. DNA Mismatch Repair 10%
24. Pathologists 10%
25. Lymph Nodes 10%
26. Biomarkers 10%
27. Residual Neoplasm 9%
28. Nivolumab 9%
29. Immunity 9%
30. Cyclophosphamide 8%
31. Macrophages 8%
32. Cancer Vaccines 8%
33. Pancreatic Intraductal Neoplasms 8%
34. Radiosurgery 7%
35. Cyst Fluid 7%
36. Antibodies 7%
37. Hydrogels 7%
38. Pandemics 7%
39. Tertiary Lymphoid Structures 7%
40. guadecitabine 7%
41. Oncogenes 6%
42. Breast Neoplasms 6%
43. Sarcoma 6%
44. Progression-Free Survival 6%
45. Active Immunotherapy 6%
46. Vaccines 6%
47. durvalumab 6%
48. pembrolizumab 6%
49. cediranib 6%
50. Radium-223 5%